# Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07096778/  
OnCo record `nct07096778` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Inobrodib run by CellCentric Ltd., now recruiting.

## Summary

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07096778 by CellCentric Ltd., with 100 participants planned, started 2026-01-22, primary completion expected 2029-12-01. Conditions recorded: Multiple Myeloma Refractory, Multiple Myeloma in Relapse. Interventions recorded: Inobrodib, Pomalidomide, Dexamethasone.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07096778
- Phase: 2
- Setting: A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: CellCentric Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07096778: https://clinicaltrials.gov/study/NCT07096778

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Inobrodib](https://onco.cc/drugs/inobrodib/)
- companies: [CellCentric](https://onco.cc/companies/cellcentric/)

---
JSON: https://onco.cc/api/v1/entities/nct07096778.json